Belgium Liver Cancer Therapeutics Market Report 2022 to 2030

Belgium Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Belgium Liver Cancer Therapeutics market will reach a value of $23.6 Mn from $6.4 Mn in 2022, growing at a CAGR of 17.6 % during 2022-2030. Liver Cancer Therapeutics in Belgium is dominated by a few domestic pharmaceutical companies such as IBA Molecular, OncoDNA and Theraclion. The Liver Cancer Therapeutics market in Belgium is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Belgium Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10BEPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Dr. Vishwa Modhia

Buy Now

Belgium Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Belgium Liver Cancer Therapeutics market will reach a value of $23.6 Mn from $6.4 Mn in 2022, growing at a CAGR of 17.6 % during 2022-2030.

Belgium is a high-income, developed country in Western Europe that borders the North Sea. About 9.4% of the estimated malignancies in Belgium were liver cancers caused by alcohol consumption. The Belgian Cancer Plan 2020-2025 intends to enhance liver cancer prevention, diagnosis, and treatment in Belgium, with a focus on raising awareness of the disease and introducing screening programmes for at-risk populations.

According to the Belgian Cancer Registry, roughly 1,500 new cases of liver cancer were diagnosed in Belgium in 2018, with a fatality rate of around 1,300 persons. In Belgium, liver cancer is the sixth leading cause of cancer-related death. According to the most recent WHO data, 976 people died from liver cancer in Belgium in 2020, accounting for 1.05 % of all deaths. Belgium ranks 137th in the world with an age-adjusted death rate of 3.89 per 100,000 population. Belgium’s government spent 11.1 % of its GDP on healthcare in 2020.

Belgium Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Tobacco use is a risk factor for liver cancer. Smoking is prevalent in Belgium, particularly among men. In general, cancer treatments in Belgium are compensated under a system known as "convention status," which implies that the costs of the treatment are covered entirely or partially by the national health insurance system. In terms of commerce, Belgium is strategically placed between the United Kingdom, Germany, and France. It also has a well-trained workforce due to vocational education and multilingualism. These aspects could boost Belgium's Liver Cancer Therapeutics market.

Market Restraints

Clinical studies can assist to enhance liver cancer treatment and improve results, yet clinical trials may be few in Belgium. This may limit patients with liver cancer's access to novel medicines. Belgium has severe structural unemployment, and there are political and financial tensions between Flanders and Wallonia. These factors may deter new entrants into the Belgium Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

IBA Molecular: IBA Molecular is a Belgian company that specializes in the development and production of radiopharmaceuticals for cancer diagnosis and treatment, including liver cancer
OncoDNA: OncoDNA is a Belgian company that provides genomic testing services to help oncologists personalize cancer treatment. The company's OncoDEEP liver test is designed to identify genetic mutations and other biomarkers that can guide treatment decisions for patients with liver cancer
Theraclion: Theraclion is a French medical device company with a subsidiary in Belgium that develops and commercializes innovative ultrasound technologies for the treatment of a variety of medical conditions, including liver cancer
PharmaMar: PharmaMar is a Spanish biopharmaceutical company with a presence in Belgium that develops and markets cancer therapies based on marine-derived compounds
Ion Beam Applications (IBA): IBA is a Belgian company that develops and manufactures particle accelerators for medical and industrial applications

Recent Notable Updates

March 2022: OncoDNA and Synlab collaborate to make comprehensive biomarker testing for cancer therapy selection more accessible in Germany. OncoDNA and Synlab will collaborate to provide doctors with high-quality pan-cancer biomarker testing for the management of their patients. OncoDEEP is a comprehensive test that predicts patient response to a wide range of approved and investigational medicines in a single test, as opposed to single biomarker testing.

Healthcare Policies and Reimbursement Scenarios

The Federal Agency for Medicines and Health Products (FAMHP) regulates liver cancer therapies in Belgium. The FAMHP is in charge of ensuring the safety, efficacy, and quality of medical products in the country. Before novel medications and therapies may be commercialised in Belgium, the FAMHP studies and approves them, and it also monitors their safety and effectiveness after they are approved. In general, cancer treatments in Belgium are compensated under a system known as "convention status," which implies that the costs of the treatment are covered entirely or partially by the national health insurance system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.